<DOC>
	<DOC>NCT01478269</DOC>
	<brief_summary>This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.</brief_summary>
	<brief_title>Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. Histologically confirmed newly diagnosed aggressive Bcell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007. 2. Any stage of disease. 3. Treatment with RCHOP or RCHOP like regimens (+/ transplant). 4. Age at least 18 years. 5. Availability of tissue biopsy at diagnosis for a possible centralized revision. 6. Availability of data on clinical involvement, laboratory, treatment and follow up.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Aggressive B-cell lymphoma</keyword>
	<keyword>R-CHOP</keyword>
</DOC>